Braveheart Bio, Inc. (BRVE) SEC filings
BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$19.62−0.88 (-4.29%)
Close on Nov 13, 2026Market cap $1.77BP/E –Yield –
SEC filings
6 of Braveheart Bio's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Quarterly report | 10-Q | Sep 30, 2026 | Nov 10, 2026 | SEC EDGAR |
| Current report | 8-K | Nov 10, 2026 | Nov 10, 2026 | SEC EDGAR |
| Current report | 8-K | Nov 6, 2026 | Nov 6, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2026 | Sep 8, 2026 | SEC EDGAR |
| Current report | 8-K | Sep 8, 2026 | Sep 8, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 5, 2026 | Aug 7, 2026 | SEC EDGAR |
See a number that looks wrong?